Business Context and Reporting Period
This Form 8-K Current Report is filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on July 24, 2019, regarding events occurring on July 23 and July 24, 2019. The Company is an emerging growth company incorporated in Delaware. The filing primarily addresses a material modification of security holder rights via a reverse stock split and the results of the 2019 Annual Meeting of Stockholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes
- Reverse Stock Split: The Company effected a 1-for-10 reverse stock split of its common stock effective July 24, 2019. Every ten shares of common stock were reclassified into one new share. Fractional shares were rounded up to the nearest whole share without cash payment.
- Purpose: The split was implemented to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Global Market.
- Trading Adjustments: Trading resumed on a split-adjusted basis on July 25, 2019, under the existing symbol "OBLN" with a new CUSIP number (67424L209).
- Equity Adjustments: Proportionate adjustments were made to conversion and exercise prices of outstanding equity awards and options.
Corporate Actions and Governance
At the Annual Meeting held on July 23, 2019, stockholders voted on three proposals:
- Proposal 1 (Director Election): Stockholders elected Kim Kamdar, Ph.D., and Andrew Rasdal as Class III Directors.
- Proposal 2 (Reverse Stock Split Authorization): Stockholders approved the Board's authority to effect a reverse stock split at a ratio between 1-for-5 and 1-for-20. The Board subsequently selected the 1-for-10 ratio.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Investor Verification Checklist
- Verify the new CUSIP number (67424L209) for post-split trading.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-10 consolidation.
- Review the impact of the split on the exercise price and share count of any outstanding stock options or warrants.
- Monitor the stock price to ensure continued compliance with Nasdaq Global Market minimum bid price requirements.